Phase I/II study of topotecan (SKF 104864) with recombinant GM-CSF (sargramostim) used as a priming agent in advanced malignancies
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Sargramostim (Primary) ; Topotecan (Primary)
- Indications Cancer
- Focus Adverse reactions
- 13 Aug 2020 Status changed from active, no longer recruiting to completed.
- 21 Sep 2005 New trial record.